var data={"title":"Loperamide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Loperamide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6477?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=loperamide-drug-information\" class=\"drug drug_general\">see &quot;Loperamide: Drug information&quot;</a> and <a href=\"topic.htm?path=loperamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Loperamide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51062736\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Loperamide Safety Alert</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA continues to receive reports of serious heart problems and deaths with use of higher than recommended doses of loperamide, primarily among people who are intentionally misusing or abusing the product. To encourage safe use, the FDA is working with loperamide manufacturers to use blister packs or other single-dose packaging and to limit the number of doses in a package.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Providers should counsel patients to take loperamide only as prescribed or according to the OTC Drug Facts label, and advise patients that drug interactions with commonly used medicines may increase the risk of serious cardiac events.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information can be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm594403.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPG6jnWVdkJ4rlHSePh6VTLmOhyJ+Nznygvd8P/bvekGQX5dujULjGxVyhOXYIw1Bh9i85TeA+aP+CDg+ZuBgVnkMgZe9FQL16ZtaFtrRrlR70/GkkQYj1qvXyZoI5PgDxw==&amp;TOPIC_ID=12561\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm594403.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49184879\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Torsades de pointes and sudden death</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cases of torsades de pointes, cardiac arrest, and death have been reported with the use of a higher than recommended dosage of loperamide.</p>\n        <p style=\"text-indent:0em;\">Loperamide is contraindicated in pediatric patients &lt;2 years of age.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Avoid dosages higher than recommended in adults and pediatric patients &ge;2 years due to the risk of serious cardiac adverse reactions.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189683\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Anti-Diarrheal [OTC];</li>\n      <li>Diamode [OTC];</li>\n      <li>Imodium A-D [OTC];</li>\n      <li>Loperamide A-D [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189684\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Loperamide;</li>\n      <li>Diarr-Eze;</li>\n      <li>Dom-Loperamide;</li>\n      <li>Imodium;</li>\n      <li>Loperacap;</li>\n      <li>Novo-Loperamide;</li>\n      <li>PMS-Loperamine;</li>\n      <li>Rho-Loperamine;</li>\n      <li>Rhoxal-loperamide;</li>\n      <li>Riva-Loperamide;</li>\n      <li>Sandoz-Loperamide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059857\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidiarrheal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059852\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=loperamide-drug-information\" class=\"drug drug_general\">see &quot;Loperamide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Acute diarrhea:</b> Oral: Children &ge;2 years and Adolescents:  <b>Note:</b> For patients small for chronological age, may consider dosing according to weight range and not by age group. Use lowest effective dose for shortest duration. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">2-5 years weighing 13 to &lt;21 kg: Initial: 1 mg with first loose stool followed by 1 mg/dose after each subsequent loose stool; maximum daily dose: 3 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">6-8 years weighing 21-27 kg: Initial: 2 mg with first loose stool followed by 1 mg/dose after each subsequent loose stool; maximum daily dose: 4 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">9-11 years weighing 27.1-43 kg: Initial: 2 mg with first loose stool followed by 1 mg/dose after each subsequent loose stool; maximum daily dose: 6 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;12 years and Adolescents: Initial: 4 mg with first loose stool followed by 2 mg/dose after each subsequent loose stool; maximum daily dose: 8 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Chronic diarrhea; secondary to intestinal failure, short-bowel syndrome, or other noninfectious causes:</b> Limited data available; dosing regimens variable: Oral: Infants &ge;2 months and Children: 0.08-0.24 mg/kg/day divided 2-3 times/day was reported in a case series of 10 pediatric patients (age range: 2-52 months) (Buts, 1975). In a case-series of six infants and young children, higher dosing was described: Initial: 1-1.5 mg/kg/day in 4 divided doses with subsequent dose decreased as stool output and diet tolerance improved and patient weight increased. Reported final dose range of 0.25-0.5 mg/kg/day in 2 divided doses was used long-term until patient achieved target weight and dietary goals; reported duration of therapy: 6 months to ~2 years (Sandhu, 1983); maximum single dose:  2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b> Irinotecan-induced (delayed) diarrhea:</b> Limited data available; consult individual protocols; some organizations have used the following: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Fixed dosing (Children&rsquo;s Oncology Group recommendation):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children &ge;2-12 years: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&lt;13 kg: Initial: 0.5 mg after the first loose bowel movement, followed by 0.5 mg every 3 hours while awake; during the night, may administer every 4 hours; maximum daily dose: 4 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">13 kg to &lt;20 kg: Initial: 1 mg after the first loose bowel movement, followed by 1 mg every 4 hours; maximum daily dose: 6 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">20 kg to &lt;30 kg: Initial: 2 mg after the first loose bowel movement, followed by 1 mg every 3 hours while awake; during the night, may administer every 4 hours; maximum daily dose: 8 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">30 kg to &lt;43 kg:  Initial: 2 mg after the first loose bowel movement, followed by 1 mg every 2 hours while awake; during the night, may administer every 4 hours; maximum daily dose: 12 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents weighing &ge;43 kg: Initial: 4 mg after the first loose bowel movement, followed by 2 mg after each loose stool; maximum daily dose: 16 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Weight-based dosing: Children and Adolescents 2 to &lt;15 years (Vassal, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Grade 1 or 2: 0.03 mg/kg/dose every 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Grade 3 or 4: 0.06 mg/kg/dose every 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Maximum single dose dependent upon weight</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&lt;13 kg:  0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">13 to &lt;20 kg: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">20 to &lt;43 kg:  Initial: 2 mg; subsequent doses: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&ge;43 kg:  Initial: 4 mg; subsequent doses: 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Acute diarrhea:</b> Oral: Initial: 4 mg, followed by 2 mg after each loose stool, up to 16 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Chronic diarrhea:</b> Oral: Initial: Follow acute diarrhea; maintenance dose should be slowly titrated downward to minimum required to control symptoms (typically, 4-8 mg/day in divided doses)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Traveler's diarrhea:</b> Oral: Initial: 4 mg after first loose stool, followed by 2 mg after each subsequent stool (maximum dose: 8 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer labeling. Due to possible effects on first-pass metabolism, use with caution and monitor closely for signs of CNS toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189665\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [contains brilliant blue fcf (fd&amp;c blue #1), peg-40 hydrogenated castor oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 1 mg/7.5 mL (30 mL [DSC], 120 mL, 240 mL, 360 mL [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 1 mg/7.5 mL (120 mL, 240 mL) [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), propylene glycol, sodium benzoate; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/5 mL (5 mL, 10 mL, 118 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/7.5 mL (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [contains brilliant blue fcf (fd&amp;c blue #1), corn starch, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [scored; contains brilliant blue fcf (fd&amp;c blue #1), corn starch, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [scored; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diamode: 2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [DSC] [scored; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [DSC] [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loperamide A-D: 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [DSC] [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189652\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059861\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Drink plenty of fluids to help prevent dehydration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127376\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059860\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute diarrhea including traveler&rsquo;s diarrhea (FDA approved in ages &ge;2 years and adults; OTC use: FDA approved in ages &ge;6 years and adults); treatment of chronic diarrhea associated with inflammatory bowel disease (FDA approved in adults); has also been used for chronic functional diarrhea (idiopathic), chronic diarrhea caused by short bowel syndrome or organic lesions; to decrease the volume of ileostomy discharge; management of antiretroviral-induced diarrhea and irinotecan-induced (late-onset) diarrhea </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189734\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D may be confused with Indocin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loperamide may be confused with furosemide, Lomotil</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Indiaral [France] may be confused with Inderal and Inderal LA brand names for propranolol [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lomotil: Brand name for loperamide [Mexico, Philippines], but also the brand name for diphenoxylate [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lomotil [Mexico, Phillipines] may be confused with Ludiomil brand name for maprotiline [multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189732\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, constipation, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal discomfort, abdominal distention, abdominal pain, anaphylactic shock, anaphylactoid reaction, angioedema, bullous rash (rare), drowsiness, dyspepsia, erythema multiforme (rare), fatigue, flatulence, hypersensitivity reaction, megacolon, paralytic ileus, pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), toxic megacolon, urinary retention, urticaria, vomiting, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189671\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to loperamide or any component of the formulation; abdominal pain without diarrhea; children &lt;2 years; acute dysentery; acute ulcerative colitis; bacterial enterocolitis (caused by <i>Salmonella</i>, <i>Shigella</i>, and <i>Campylobacter</i>); pseudomembranous colitis associated with broad-spectrum antibiotic use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use if stool is bloody or black.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for antidiarrheals is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189656\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic reactions: Rare cases of anaphylaxis and anaphylactic shock have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause drowsiness or dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Discontinue promptly if constipation, abdominal pain, abdominal distension, blood in stool, or ileus develop. Do not use when peristalsis inhibition should be avoided due to potential for ileus, megacolon and/or toxic megacolon.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Torsades de pointes and sudden death: <b>[US Boxed Warning]: Cases of torsades de pointes, cardiac arrest, and death have been reported with the use of a higher than recommended dosage. Contraindicated in pediatric patients &lt;2 years. Avoid dosages higher than recommended in patients &ge;2 years due to the risk of serious cardiac adverse reactions.</b> Cases of syncope and ventricular tachycardia have been reported in adults receiving the recommended dose of loperamide. Cases of cardiac arrest, syncope, and respiratory depression have been reported in pediatric patients &lt;2 years. Avoid use in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of cardiac arrhythmias or other cardiac conditions, elderly, electrolyte abnormalities) and in combination with others drugs known to prolong the QT interval.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; AIDS patients: Stop therapy at the first sign of abdominal distention; cases of toxic megacolon have occurred in AIDS patients with infectious colitis (due to viral or bacterial pathogens).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment due to reduced first-pass metabolism; monitor for signs of CNS toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more susceptible to drug-associated effects on the QT interval.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in young children as response may be variable because of dehydration. Contraindicated in children &lt;2 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Loperamide is a symptom-directed treatment; if an underlying diagnosis is made, other disease-specific treatment may be indicated. Concurrent fluid and electrolyte replacement is often necessary in all age groups depending upon severity of diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of use: If diarrhea lasts longer than 2 days, symptoms worsen, or abdominal swelling or bulging develops, discontinue use and consult healthcare provider.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self medication (OTC use): Consult health care provider prior to using, if taking antibiotics, if pregnant or breastfeeding, or in the presence of fever, mucus in stool, or a history of liver disease. Serious heart problems may occur if taken more than directed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022359\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">When managing acute dysentary, concurrent fluid and electrolyte replacement is often necessary in all age groups depending upon severity of diarrhea; young pediatric patients are particularly susceptible to dehydration and electrolyte imbalances. Antidiarrheal agents are not recommended as part of the management of acute gastroenteritis in infants and children because they do not address the underlying cause (ie, do not treat the infection) and have a risk of serious adverse events (CDC, 2003). A metaanalysis evaluating the use of loperamide for adjunct treatment of acute bacterial gastroenteritis in pediatric patients identified that infants and children &lt;3 years, malnourished, moderately to severely dehydrated, or those with bloody diarrhea have a higher risk of serious adverse events (ileus, lethargy, death) even at therapeutic doses (&le;0.25 mg/kg/day of loperamide) and that the potential benefit of loperamide therapy does not outweigh risks; use should be avoided in this subset of pediatric patients (Li, 2007). The manufacturer recommends to avoid use in infants and children &lt;2 years. Older children with milder infection and adolescents may see benefit from loperamide therapy including decreased duration of diarrhea and stool counts; monitor closely for adverse effects or worsening of infection (CDC, 2003; Li, 2007). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127373\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189661\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12561&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Loperamide-Loperamide Oxide may increase the serum concentration of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Loperamide-Loperamide Oxide may enhance the constipating effect of Eluxadoline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Loperamide-Loperamide Oxide may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189662\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127372\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have not been observed in animal reproduction studies. Information related to loperamide use in pregnancy is limited and data is conflicting (Einarson 2000; K&auml;ll&eacute;n 2008). For acute diarrhea in pregnant women, some clinicians recommend oral rehydration and dietary changes; loperamide in small amounts may be used only if symptoms are disabling (Wald 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189655\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acts directly on circular and longitudinal intestinal muscles, through the opioid receptor, to inhibit peristalsis and prolong transit time; reduces fecal volume, increases viscosity, and diminishes fluid and electrolyte loss; demonstrates antisecretory activity. Loperamide increases tone on the anal sphincter</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189670\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Poor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Poor penetration into brain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via oxidative N-demethylation; CYP2C8 and CYP3A4 (major) and CYP2B6 and CYP2D6 (minor) role in N-demethylation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 9.1 to 14.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Liquid: 2.5 hours; Capsule: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189673\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Imodium A-D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (24): $11.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Loperamide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $104.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Imodium A-D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/7.5 mL (120 mL): $5.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Loperamide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/5 mL (5 mL): $1.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Imodium A-D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (24): $10.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Loperamide A-D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (12): $1.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189674\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abydium (LK);</li>\n      <li>Albutil (BD);</li>\n      <li>Arret (IE);</li>\n      <li>Beamodium (MY);</li>\n      <li>Betaperamide (ZA);</li>\n      <li>Binaldan (CH);</li>\n      <li>Cicamin (PY);</li>\n      <li>Colidium (ID);</li>\n      <li>Colifilm (AR);</li>\n      <li>Coliper (CL);</li>\n      <li>Colodium (HK);</li>\n      <li>Contem (PY);</li>\n      <li>D-Stop-ratiopharm (LU);</li>\n      <li>Degortkap (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Diadium (ID);</li>\n      <li>Diamide (NZ);</li>\n      <li>Diaperol (MX);</li>\n      <li>Diareze (AU);</li>\n      <li>Diarlop (IN);</li>\n      <li>Diarodil (TH);</li>\n      <li>Diatabs (PH);</li>\n      <li>Diatrol (SG);</li>\n      <li>Dissenten (IT);</li>\n      <li>Donafan (PE);</li>\n      <li>Donamed F (PE);</li>\n      <li>Dyspagon (LU);</li>\n      <li>Elcoman (AR);</li>\n      <li>Fortasec (ES);</li>\n      <li>Gastro-Stop (AU);</li>\n      <li>Gastron (ZA);</li>\n      <li>Harmonise (AU);</li>\n      <li>Hocular (TW);</li>\n      <li>Hrindeks (UA);</li>\n      <li>Imodium (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, CH, CI, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Imodonil (HK);</li>\n      <li>Imonox (TH);</li>\n      <li>Imosec (BR);</li>\n      <li>Imosen (TW);</li>\n      <li>Imossel (FR);</li>\n      <li>Imotil (LK);</li>\n      <li>Inamid (ID);</li>\n      <li>Lenide-T (ZA);</li>\n      <li>Lockit (ZW);</li>\n      <li>Lodia (ID);</li>\n      <li>Lomedium (VN);</li>\n      <li>Lomid (BD);</li>\n      <li>Lomotil (MX);</li>\n      <li>Loniper (PH);</li>\n      <li>Lopamid (BD, ID);</li>\n      <li>Lopamide (ET, IN);</li>\n      <li>Lopedin (TW);</li>\n      <li>Lopedium (HU, LU);</li>\n      <li>Lopemid (IT);</li>\n      <li>Loper (HK);</li>\n      <li>Loperamid-ratiopharm (LU);</li>\n      <li>Loperamide-Eurogenerics (LU);</li>\n      <li>Loperamide-Generics (LU);</li>\n      <li>Loperamil (HK, SG);</li>\n      <li>Loperhoe (DE);</li>\n      <li>Loperium (BB, BM, BS, BZ, GY, JM, MT, NL, SR, TT);</li>\n      <li>Lopermid (TR);</li>\n      <li>Lopermide (HK);</li>\n      <li>Lopicare (IL);</li>\n      <li>Lopide (BD);</li>\n      <li>Lopmin (KR);</li>\n      <li>Lopodium (QA);</li>\n      <li>Loprex (IL);</li>\n      <li>Loprid (RO);</li>\n      <li>Lopron (PH);</li>\n      <li>Loramide (LK, SG);</li>\n      <li>Lordiar (HR);</li>\n      <li>Lorid (BD);</li>\n      <li>Luobaomai (CN);</li>\n      <li>Motilex (ID);</li>\n      <li>NT-Diorea (HK);</li>\n      <li>Pangetan NF (CO);</li>\n      <li>Paradoxone (ET);</li>\n      <li>Perasian (TH);</li>\n      <li>Permid (PH);</li>\n      <li>Ramide (ET);</li>\n      <li>Regulane (AR);</li>\n      <li>Rexamide (IL);</li>\n      <li>Reximide (MY);</li>\n      <li>Rhomuz (ID);</li>\n      <li>Safe (TW);</li>\n      <li>Salvacolina (ES);</li>\n      <li>Sanpo (TW);</li>\n      <li>Seldiar (HR);</li>\n      <li>Shilshul X2 (IL);</li>\n      <li>Stoperan (UA);</li>\n      <li>Stopit (IL);</li>\n      <li>Suprasec (AR);</li>\n      <li>Tarmin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Toban (PE);</li>\n      <li>Toban F (PE);</li>\n      <li>Undiarrhea (TW);</li>\n      <li>Vacontil (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, JO, KE, KW, LB, LR, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SC, SD, SL, SN, TN, TZ, UG, VN, ZM, ZW);</li>\n      <li>Vancotil (SG);</li>\n      <li>Velaral (EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buts JP, Petit BF, and de Meyer R, &quot;Letter: Loperamide in Treatment of Persistent Diarrhoea in Children,&quot; <i>Br Med J</i>, 1975, 3(5986):766-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/1174894/pubmed\" target=\"_blank\" id=\"1174894\">1174894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Managing Acute Gastroenteritis Among Children: Oral Rehydration, Maintenance, and Nutritional Therapy,&quot; <i>MMWR Recomm Rep</i>, 2003, 52(RR-16):1-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/14627948/pubmed\" target=\"_blank\" id=\"14627948\">14627948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Einarson A, Mastroiacovo P, Arnon J, et al, &quot;Prospective, Controlled, Multicentre Study of Loperamide in Pregnancy,&quot; <i>Can J Gastroenterol</i>, 2000, 14(3):185-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/10758415/pubmed\" target=\"_blank\" id=\"10758415\">10758415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamdi I and Dodge JA, &quot;Toddler Diarrhoea: Observations on the Effects of Aspirin and Loperamide,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 1985, 4(3):362-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/3926980/pubmed\" target=\"_blank\" id=\"3926980\">3926980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;ll&eacute;n B, Nilsson E, and Otterblad Olausson P, &quot;Maternal Use of Loperamide in Early Pregnancy and Delivery Outcome,&quot; <i>Acta Paediatr</i>,  2008, 97(5):541-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/18394096/pubmed\" target=\"_blank\" id=\"18394096\">18394096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li ST, Grossman DC, and Cummings P, &quot;Loperamide Therapy for Acute Diarrhea in Children: Systematic Review and Meta-analysis,&quot; <i>PLoS Med</i>, 2007, 4(3):e98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/17388664/pubmed\" target=\"_blank\" id=\"17388664\">17388664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nikodem VC and Hofmeyr GJ, &quot;Secretion of the Antidiarrhoeal Agent Loperamide Oxide in Breast Milk,&quot; <i>Eur J Clin Pharmacol</i>, 1992, 42(6):695-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/1623917/pubmed\" target=\"_blank\" id=\"1623917\">1623917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandhu BK, Tripp JH, Milla PJ, et al, &quot;Loperamide in Severe Protracted Diarrhoea,&quot; <i>Arch Dis Child</i>, 1983, 58(1):39-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/6830273/pubmed\" target=\"_blank\" id=\"6830273\">6830273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vassal G, Couanet D, Stockdale E, et al, &quot;Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group,&quot; <i>J Clin Oncol</i>, 2007, 25(4):356-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/17264330/pubmed\" target=\"_blank\" id=\"17264330\">17264330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wald A, &quot;Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy,&quot; <i>Gastroenterol Clin North Am</i>, 2003, 32(1):309-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-pediatric-drug-information/abstract-text/12635420/pubmed\" target=\"_blank\" id=\"12635420\">12635420</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12561 Version 181.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F51062736\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F49184879\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F189683\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F189684\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059857\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059852\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F189665\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F189652\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059861\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2127376\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059860\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189734\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F189732\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F189671\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189656\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022359\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F2127373\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189661\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F189662\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2127372\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189655\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F189670\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F189673\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F189674\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12561|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=loperamide-drug-information\" class=\"drug drug_general\">Loperamide: Drug information</a></li><li><a href=\"topic.htm?path=loperamide-patient-drug-information\" class=\"drug drug_patient\">Loperamide: Patient drug information</a></li></ul></div></div>","javascript":null}